Filing Flows › Aligos Therapeutics (ALGS) › Q1 2025
Aligos Therapeutics (ALGS) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 6, 2025
Aligos Therapeutics (ALGS) reported revenue of $311K for the first quarter 2025 (Q1 2025), -55% from a year earlier and -49% from the quarter before.
Aligos Therapeutics, Q1 2025: revenue $311K (-55% year over year), net earnings $43.1M, operating cash flow −$20.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $311K | -49% | -55% |
| Operating profit | −$19.2M | — | — |
| Net earnings | $43.1M | — | — |
| Operating cash flow | −$20.9M | — | — |
What changed
Revenue was $311K in Q1 2025, down 55% year over year and down 49% from the previous quarter.
Operating costs exceeded revenue by $19.2M, an operating margin of -6187.5%. Total costs fell 14% while revenue fell 55%. Net earnings were $43.1M. The effective tax rate was 0.1%. Non-operating items added $62.4M, 145% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$20.9M. Non-cash charges added back $194K of depreciation and $1.0M of share-based compensation. Working capital and other items used $65.2M.
Questions
What was Aligos Therapeutics' revenue in the first quarter 2025?
Aligos Therapeutics (ALGS) reported revenue of $311K for the first quarter 2025 (Q1 2025), -55% from a year earlier and -49% from the quarter before.